Receipt of $3.8M R&D Tax Incentive
Filed with ASX · · 2 pages · English
Story so far
Earlier from OncoSil Medical
- Appendix 4E and Full Year Statutory Accounts
- Response to ASX Price Query
- Update - CE Marking Application
- CE Marking Update
- PanCo Study Interim Analysis
Later from OncoSil Medical
- OncoSil AGM CEO Presentation
- Positive CE Mark Status Report
- CE Mark Update
- FDA Grants Breakthrough Device Designation
- Pause in Trading
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical